ClinicalTrials.gov
ClinicalTrials.gov Menu

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01780662
Recruitment Status : Active, not recruiting
First Posted : January 31, 2013
Last Update Posted : June 26, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)